Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT06166589
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Previously AG Chemotherapy Treated Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zimberelimab — DRUG
    Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
  • Oxaliplatin — DRUG
    Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
  • S-1 — DRUG
    S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
  • Irinotecan — DRUG
    Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.

Study Details

This is a prospective, single arm, phase II clinical study investigating second-line Zimberelimab and SIROX chemotherapy for patient with previously AG chemotherapy treated pancreatic cancer.

Key Dates

Start date
Jan 1, 2024
Status verified
Dec 2023
Primary completion
Jan 1, 2026
Completion
Jan 1, 2027

Study Design

Enrollment
19 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zimberelimab in combination with SIROX chemotherapy

Primary Outcome Measure

ORR [ Time Frame: one year ]

Central Contacts